130 related articles for article (PubMed ID: 26328452)
1. Nanoencapsulation of Clobetasol Propionate Decreases Its Penetration to Skin Layers Without Changing Its Relative Skin Distribution.
de Andrade DF; Fontana MC; Pohlmann AR; Guterres SS; Carlos R; Beck R
J Nanosci Nanotechnol; 2015 Jan; 15(1):875-9. PubMed ID: 26328452
[TBL] [Abstract][Full Text] [Related]
2. Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate.
Fontana MC; Rezer JF; Coradini K; Leal DB; Beck RC
Eur J Pharm Biopharm; 2011 Oct; 79(2):241-9. PubMed ID: 21605671
[TBL] [Abstract][Full Text] [Related]
3. Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects.
Mathes C; Melero A; Conrad P; Vogt T; Rigo L; Selzer D; Prado WA; De Rossi C; Garrigues TM; Hansen S; Guterres SS; Pohlmann AR; Beck RCR; Lehr CM; Schaefer UF
J Control Release; 2016 Feb; 223():207-214. PubMed ID: 26686081
[TBL] [Abstract][Full Text] [Related]
4. Clobetasol-loaded nanostructured lipid carriers for epidermal targeting.
Silva LA; Andrade LM; de Sá FA; Marreto RN; Lima EM; Gratieri T; Taveira SF
J Pharm Pharmacol; 2016 Jun; 68(6):742-50. PubMed ID: 27061573
[TBL] [Abstract][Full Text] [Related]
5. Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers.
Melero A; Ferreira Ourique A; Stanisçuaski Guterres S; Raffin Pohlmann A; Lehr CM; Ruver Beck RC; Schaefer U
Skin Pharmacol Physiol; 2014; 27(4):217. PubMed ID: 24751514
[TBL] [Abstract][Full Text] [Related]
6. Polymeric Nanocapsules and Lipid-Core Nanocapsules Have Diverse Skin Penetration.
de Brum TL; Fiel LA; Contri RV; Guterres SS; Pohlmann AR
J Nanosci Nanotechnol; 2015 Jan; 15(1):773-80. PubMed ID: 26328441
[TBL] [Abstract][Full Text] [Related]
7. Assessing the In Vitro Drug Release from Lipid-Core Nanocapsules: a New Strategy Combining Dialysis Sac and a Continuous-Flow System.
de Andrade DF; Zuglianello C; Pohlmann AR; Guterres SS; Beck RC
AAPS PharmSciTech; 2015 Dec; 16(6):1409-17. PubMed ID: 25986595
[TBL] [Abstract][Full Text] [Related]
8. Different approaches for improving skin accumulation of topical corticosteroids.
Senyiğit T; Padula C; Ozer O; Santi P
Int J Pharm; 2009 Oct; 380(1-2):155-60. PubMed ID: 19635541
[TBL] [Abstract][Full Text] [Related]
9. Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin.
Senyiğit T; Sonvico F; Barbieri S; Ozer O; Santi P; Colombo P
J Control Release; 2010 Mar; 142(3):368-73. PubMed ID: 19932722
[TBL] [Abstract][Full Text] [Related]
10. The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol 17-propionate in vivo.
Watson WS; Finlay AY
Br J Dermatol; 1988 Apr; 118(4):523-30. PubMed ID: 3377973
[TBL] [Abstract][Full Text] [Related]
11. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo--part II: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies.
Patel HK; Barot BS; Parejiya PB; Shelat PK; Shukla A
Colloids Surf B Biointerfaces; 2014 Jul; 119():145-53. PubMed ID: 24767976
[TBL] [Abstract][Full Text] [Related]
12. Prolonged skin retention of clobetasol propionate by bio-based microemulsions: a potential tool for scalp psoriasis treatment.
Langasco R; Tanrıverdi ST; Özer Ö; Roldo M; Cossu M; Rassu G; Giunchedi P; Gavini E
Drug Dev Ind Pharm; 2018 Mar; 44(3):398-406. PubMed ID: 29098874
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of Clobetasol-17-Propionate in Psoriatic Lesional and Non-Lesional Skin Assessed by Dermal Open Flow Microperfusion with Time and Space Resolution.
Bodenlenz M; Dragatin C; Liebenberger L; Tschapeller B; Boulgaropoulos B; Augustin T; Raml R; Gatschelhofer C; Wagner N; Benkali K; Rony F; Pieber T; Sinner F
Pharm Res; 2016 Sep; 33(9):2229-38. PubMed ID: 27271272
[TBL] [Abstract][Full Text] [Related]
14. Topical application of clobetasol 17-propionate from various cream bases by using Wistar rat as an animal model.
Fang JY; Shen KL; Huang YB; Wu PC; Tsai YH
Kaohsiung J Med Sci; 1998 May; 14(5):286-93. PubMed ID: 9619014
[TBL] [Abstract][Full Text] [Related]
15. In vitro penetration through the skin layers of topically applied glucocorticoids.
Carrer V; Alonso C; Oliver MA; Coderch L
Drug Test Anal; 2018 Oct; 10(10):1528-1535. PubMed ID: 29788546
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization.
Nagaich U; Gulati N
Drug Deliv Transl Res; 2016 Jun; 6(3):289-98. PubMed ID: 27072979
[TBL] [Abstract][Full Text] [Related]
17. Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate.
Fang J; Fang C; Sung KC; Chen H
Int J Pharm; 1999 Nov; 191(1):33-42. PubMed ID: 10556738
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Clobetasol Propionate Generics Using Simplified In vitro Bioequivalence Method for Topical Drug Products.
Soares KCC; de Souza WC; de S Texeira L; da Cunha-Filho MSS; Gelfuso GM; Gratieri T
Curr Drug Deliv; 2018; 15(7):998-1008. PubMed ID: 29165079
[TBL] [Abstract][Full Text] [Related]
19. Nanoencapsulation as a way to control the release and to increase the photostability of clobetasol propionate: influence of the nanostructured system.
Fontana MC; Coradini K; Guterres SS; Pohlmann AR; Beck RC
J Biomed Nanotechnol; 2009 Jun; 5(3):254-63. PubMed ID: 20055007
[TBL] [Abstract][Full Text] [Related]
20. Qualitative and Quantitative Study of the Potential of Lipid Nanocapsules of One Hundred Twenty Nanometers for the Topical Administration of Hydrophobic Molecules.
Nguyen HTP; Munnier E; Perse X; Vial F; Yvergnaux F; Perrier T; Soucé M; Chourpa I
J Pharm Sci; 2016 Oct; 105(10):3191-3198. PubMed ID: 27519648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
